The treatment of renal cell carcinoma (RCC), a malignancy that is typically chemoresistant, has drastically evolved with the introduction of vascular endothelial growth factor receptor tyrosine kinase ...

Prostate cancer is the most prevalent cancer among men worldwide, and there have been many advances in its diagnosis and treatment. However, critical obstacles remain, including overdiagnosis, high ...

Prostate-specific membrane antigen (PSMA) has been shown to be overexpressed in the neo-vasculature of renal cancers. However, studies investigating the pattern of PSMA expression in primary RCC and ...

Many preclinical hypotheses, including reciprocal feedback activation between AR-PI3K pathway in PTEN loss and ASI-induced "BRCAness" regardless of BRCA1/2 status, have struggled to translate into ...

Dry Mouth Prevention and Management for PSMA Radioligand Therapy "Presentation" - Sue Yom ...

To evaluate the diagnostic performance of a fully automated, commercially available AI algorithm for detecting prostate cancer and classifying lesions according to PI-RADS. In this retrospective ...

Penile squamous cell carcinoma (PSCC) is a rare, aggressive malignancy with a high risk of mortality due to metastasis. A comprehensive understanding of its mutational landscape is critical for ...

To assess the clinical application and efficacy of robotic radical prostatectomy in 50 cases of large-volume (> 100 ml) prostate cancer. A retrospective analysis was conducted on 50 patients with ...

We previously reported outcomes after hypofractionated postprostatectomy radiotherapy (HYPORT) with a median follow-up of 32 months. This was a primary citation supporting the fractionation selection ...

To evaluate the impact of treatment for localised muscle-invasive bladder cancer (MIBC) during the first 2 years after diagnosis. A prospective cohort study was conducted including patients diagnosed ...

As PSMA-PET/CT is routinely used for prostate cancer diagnosis due to its improved accuracy over traditional imaging techniques, an increasing number of non-prostate lesions are also being identified.

The treatment landscape for localized prostate cancer has evolved with the increasing use of nonradiotherapy ablative interventions (NRAIs) such as high-intensity focused ultrasound (HIFU) and ...